Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy

Qilin Huai(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Song(Chinese Academy of Medical Sciences & Peking Union Medical College), Fenglong Bie(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Liu(Sun Yat-sen University), Yuan Li(Xi'an Botanical Garden of Shaanxi Province), Xiaowei Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Xujie Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Bolun Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Guangyu Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Chenyu Luo(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cancer Science
September 20, 2023
10.1111/cas.15964
Cited by 90

Related Papers

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Mapping global prevalence of depression among postpartum women
|Translational Psychiatry|2021|670
Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America
|Cancer Letters|2021|449
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry
|Journal of Clinical Oncology|2017|358